0001477932-17-003817.txt : 20170810 0001477932-17-003817.hdr.sgml : 20170810 20170810180734 ACCESSION NUMBER: 0001477932-17-003817 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170808 FILED AS OF DATE: 20170810 DATE AS OF CHANGE: 20170810 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mazur Leonard L CENTRAL INDEX KEY: 0001463414 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38174 FILM NUMBER: 171022538 MAIL ADDRESS: STREET 1: C/O CITIUS PHARMACEUTICALS, INC. STREET 2: 11 COMMERCE DRIVE, 1ST FLOOR CITY: CRANFORD STATE: NJ ZIP: 07016 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Citius Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001506251 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273425913 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11 COMMERCE DRIVE STREET 2: 1ST FLOOR CITY: CRANFORD STATE: NJ ZIP: 07016 BUSINESS PHONE: (908) 967-6676 MAIL ADDRESS: STREET 1: 11 COMMERCE DRIVE STREET 2: 1ST FLOOR CITY: CRANFORD STATE: NJ ZIP: 07016 FORMER COMPANY: FORMER CONFORMED NAME: Trail One, Inc. DATE OF NAME CHANGE: 20110314 FORMER COMPANY: FORMER CONFORMED NAME: TrailOne, Inc. DATE OF NAME CHANGE: 20101119 4 1 form4.xml FORM 4 X0306 4 2017-08-08-06:00 false 0001506251 Citius Pharmaceuticals, Inc. CTXR 0001463414 Mazur Leonard L C//O CITIUS PHARMACEUTICALS, INC. 11 COMMERCE DRIVE, 1ST FLOOR CRANFORD NJ 07016 true true true false Executive Chairman Common Stock 2017-08-08-06:00 4 P false 421400 4.125 A 1779663 D Common Stock 2017-08-08-06:00 4 C false 1547067 3.09 A 3326730 D Warrant to Purchase Common Stock 4.125 2017-08-08-06:00 4 P false 421400 0.01 A 2018-02-08-07:00 2022-08-08-06:00 Common Stock 421400 421400 D Convertible Promissory Note 3.09 2017-08-08-06:00 4 A false 1547067 A 2017-08-08-06:00 2017-12-31-07:00 Common Stock 1547067 1547067 D Convertible Promissory Note 3.09 2017-08-08-06:00 4 C false 1547067 D 2017-08-08-06:00 2017-12-31-07:00 Common Stock 1547067 0 D Warrant to Purchase Common Stock 6.15 2019-06-12-06:00 Common Stock 19614 19614 D Warrant to Purchase Common Stock 9.90 2019-09-30-06:00 Common Stock 3171 3171 D Warrant to Purchase Common Stock 9.90 2020-01-08-07:00 Common Stock 4984 4984 D Warrant to Purchase Common Stock 7.50 2020-08-18-06:00 Common Stock 35211 35211 D Warrant to Purchase Common Stock 7.50 2020-11-02-07:00 Common Stock 20783 20783 D Warrant to Purchase Common Stock 7.50 2020-11-20-07:00 Common Stock 20664 20664 D Warrant to Purchase Common Stock 7.50 2021-01-08-07:00 Common Stock 13679 13679 D Warrant to Purchase Common Stock 7.50 2021-03-14-07:00 Common Stock 4210 4210 D Warrant to Purchase Common Stock 6.15 2021-03-15-06:00 Common Stock 18106 18106 D Options to Purchase Common Stock 6.75 2024-09-12-06:00 Common Stock 220000 220000 D On August 8, 2017, the Reporting Person purchased a five-year warrant to purchase 421,400 shares of the Company's common stock at an exercise price of $4.125 per share. The warrant is fully vested and exercisable six months from August 8, 2017. On August 8, 2017, the Reporting Person converted $4,710,000 of outstanding convertible promissory notes and accrued interest of $76,240 into shares of common stock at a conversion price per share of $3.09, which was 75% of the price per share paid by investors in the Company's public offering that was completed on August 8, 2017 as set forth in the terms of the convertible promissory notes. The warrant is fully vested and exercisable immediately. The option vests as to 40% of the shares of the Company's common stock on September 12, 2014 and 15% of the shares on each of September 12, 2015, March 12 and September 12, 2016 and September 12, 2017. The option was issued pursuant to the Company's 2014 Stock Incentive Plan. * All numbers reflect a 1-for-15 reverse stock split on June 9, 2017. /s/ Leonard L. Mazur 2017-08-10-06:00